Clinical Reliability of IgG, IgA, and IgM Antibodies in Detecting Epstein-Barr Virus at Different Stages of Infection With a Commercial Nonrecombinant Polyantigenic ELISA Gutiérrez Fernández, José Vergara, M.J. Piédrola Angulo, Gonzalo Maroto Vela, María del Carmen Epstein-Barr virus ELISA Antibodies We studied the diagnostic reliability of a modification of the Enzygnost EBV test (Behringwerke, Germany) for the detection of IgG, IgA, and IgM antibodies (Abs) in the diagnosis of Epstein-Barr virus (EBV) disease. One hundred and twenty-three serum samples were studied: 14 asymptomatic subjects without EBV infection, 48 patients with primary infection, 46 subjects with past EBV infection (11 patients with other acute infections), 8 patients without EBV infection but with other viral infection, and 7 patients with probable acute clonal stimulation of B lymphocytes caused by different microorganisms. Enzygnost EBV is based on an ELISA test with a pool of viral antigens. In our series the reliability of IgM for the diagnosis of recent primary EBV infection was: sensitivity 100%, specificity 95%, positive predictive value 90.5%, and negative predictive value 100%. The IgG detection with Enzygnost was: sensitivity 98%, specificity 100%, positive predictive value 100%, and negative predictive value 91.7%. Only two subjects had positive IgA. The Enzygnost test is an efficient method for the diagnosis of EBV infection although a few IgM false positives can occur. 2024-04-09T11:10:09Z 2024-04-09T11:10:09Z 1999-02-11 info:eu-repo/semantics/article Gutiérrez et al. Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA. J Clin Lab Anal. 1999;13(2):65-8. https://doi.org/10.1002/(SICI)1098-2825(1999)13:2<65::AID-JCLA4>3.0.CO;2-O https://hdl.handle.net/10481/90550 10.1002/(SICI)1098-2825(1999)13:2<65::AID-JCLA4>3.0.CO;2-O eng http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional Wiley